Biotia Announces AMA Proprietary Laboratory Analyses (PLA) Code Granted for BIOTIA-ID Urine NGS Assay
New York, NY – July 15, 2025 – Biotia, Inc., a health technology company specializing in microbial genomics and infectious disease diagnostics, today announced that the American Medical Association (AMA) CPT Editorial Panel has granted a new CPT® Proprietary Laboratory Analyses (PLA) code for the BIOTIA-ID Urine NGS Assay. The PLA code, 0590U, will become effective on October 1, 2025 and represents a meaningful step toward attaining health insurance reimbursement and expanded patient access.
“The issuance of a test-specific billing code allows for greater transparency in claims submission and adjudication, thereby strengthening Biotia’s commercial strategy,” said Dr. Niamh O’Hara, Chief Executive Officer and Co-founder at Biotia. “This development supports the company’s commitment to making advanced genomic diagnostic testing broadly accessible across the United States.” The BIOTIA-ID Urine NGS Assay, a next-generation sequencing-based, in-vitro diagnostic test powered by Biotia’s proprietary BIOTIA-DX software, is now available in all 50 U.S. states, including with approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP).
“This PLA code issuance by the AMA CPT Editorial Panel marks a significant milestone for Biotia and the clinicians we serve,” said Dr. Dorottya Nagy-Szakal, Chief Medical Officer at Biotia. “It enables broader insurance reimbursement opportunities and expands patient access to our genomics-based urine test, which provides a precise, comprehensive alternative for patients with recurrent and complicated urinary tract infections (UTIs) and symptomatic patients who are culture-negative.”
The BIOTIA-ID Urine NGS Assay is the first genomics-based urine assay leveraging artificial intelligence (AI) approved in all 50 states, including New York. The assay is designed to diagnose recurrent and complicated UTIs, where traditional diagnostics often fail, to guide selection of antimicrobials.
About Biotia
Biotia is a health-tech company located in New York, NY, that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Their mission is to fight infectious diseases by deploying the leading reference library of microbes worldwide. As a spinout company of Jacobs Technion-Cornell Institute at Cornell Tech, Biotia has a New York State CLIA lab for infectious disease diagnostics testing affiliated with SUNY Downstate Health Sciences University.